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ABBREVIATIONS 
 
mtDNA     mitochondrial DNA 
ΔmtDNA    mitochondrial DNA carrying a large-scale deletion 
CPEO     chronic progressive external ophthalmoplegia 
MERRF   myoclonic epilepsy with ragged-red fibers  
MELAS mitochondrial myopathy, encephalopathy, lactic acidosis, and 
stroke-like episodes 
mito-mouse    trans-mitochondrial mouse 
mito-mouse-Δ   trans-mitochondrial mouse harboring ΔmtDNA 
HAT     hypoxanthine–aminopterin–thymidine 
0      mtDNA-less 
BrdU     bromodeoxyuridine 
B6      C57BL/6J strain 
BUN     blood urea nitrogen 
RRF     ragged-red fiber 
COX     cytochrome c oxidase 
SDH     succinate dehydrogenase 
mito-mouse-tRNA
Lys7731
 trans-mitochondrial mouse harboring G7731A mtDNA 
PGD     preimplantation genetic diagnosis 
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ABSTRACT 
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I generated trans-mitochondrial mice (mito-mice) that carry a mutation in the 
tRNA
Lys
 gene encoded by mitochondrial DNA (mtDNA) for use in studies of its 
pathogenesis and transmission profiles. Because patients with mitochondrial diseases 
frequently carry mutations in the mitochondrial tRNA
Lys
 and tRNA
Leu(UUR)
 genes, I 
focused my efforts on identifying somatic mutations of these genes in mouse lung 
carcinoma P29 cells. Of the 43 clones of PCR products including the tRNA
Lys
 or 
tRNA
Leu(UUR)
 genes in mtDNA of P29 cells, one had a potentially pathogenic mutation 
(G7731A) in the tRNA
Lys
 gene. P29 subclones with predominant amounts of G7731A 
mtDNA expressed respiration defects, thus suggesting the pathogenicity of this mutation. 
I then transferred G7731A mtDNA into mouse ES cells and obtained F0 chimeric mice. 
Mating these F0 mice with C57BL/6J (B6) male mice resulted in the generation of F1 
mice with G7731A mtDNA, named ‘mito-mice-tRNALys7731’. Mito-mice-tRNALys7731 
with high proportions of G7731A mtDNA exclusively expressed respiration defects and 
disease-related phenotypes, but they expressed only muscle weakness and short body 
length by four months. I then examined the effects of their aging on metabolic and 
histologic features. Unlike young mito-mice-tRNA
Lys7731
, aged mito-mice-tRNA
Lys7731
 
developed muscle atrophy, renal failures, and various metabolic abnormalities, such as 
lactic acidosis and anemia, characteristic of patients with mitochondrial diseases. 
Moreover, the proportion of mutated mtDNA varied markedly among the pups born to 
each dam, suggesting that selecting oocytes with high proportions of normal mtDNA 
from affected mothers with tRNA
Lys
-based mitochondrial diseases may be effective as 
primary prevention for obtaining unaffected children.  
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INTRODUCTION 
 5 
 
Mitochondrial DNA (mtDNA) carrying a large-scale deletion (ΔmtDNA), 
single point mutations in the tRNA
Lys
 gene, and in the tRNA
Leu(UUR)
 gene causes CPEO 
(chronic progressive external ophthalmoplegia), MERRF (myoclonic epilepsy with 
ragged-red fibers), and MELAS (mitochondrial myopathy, encephalopathy, lactic 
acidosis, and stroke-like episodes), respectively—the three most prevalent 
mitochondrial diseases (1-3). However, there are slight differences among the three 
disease phenotypes, even though these pathogenic mtDNA mutations all induce 
mitochondrial respiration defects. Considering that mitochondrial respiratory function is 
controlled by both mitochondrial and nuclear genomes (1-3), this controversial issue 
can be clarified by generating trans-mitochondrial mice (‘mito-mice’) that share the 
same nuclear genetic background but carry different pathogenic mtDNA mutations 
corresponding to the mutations found in the three prevalent mitochondrial diseases. 
However, no well-established effective protocols are available for introducing 
mutagenized mtDNA into the mitochondria of mammalian cells.  
The previous studies (4-8) showed mtDNAs carrying pathogenic mutations in 
mouse cell lines, transferred them into mouse female germlines, and generated several 
types of mito-mice, including mito-mice-Δ (4, 5) which harbor ΔmtDNA and therefore 
are disease models for CPEO. However, mito-mice harboring mtDNA with pathogenic 
mutations in the tRNA
Lys
 and tRNA
Leu(UUR)
 genes—and therefore prospective disease 
models of MERRF and MELAS, respectively—have not previously been established 
due to the unavailability of mouse cell lines with corresponding tRNA mutations in 
mtDNA. 
To complement the paucity of effective technologies required for introducing 
mutagenized mtDNA into mitochondria of living mouse cells, I here developed an 
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alternative strategy involving cloning and sequence analysis to detect small amounts of 
mtDNA with somatic mutations in the mitochondrial tRNA genes. Because pathogenic 
mutations responsible for mitochondrial diseases occur preferentially in the tRNA
Leu(UUR)
 
and tRNA
Lys
 genes of humans (1-3), I sequenced 43 clones generated from PCR 
products carrying the mitochondrial tRNA
Leu(UUR)
 and tRNA
Lys
 genes of P29 mouse lung 
carcinoma cells (9). One of the 43 clones had a somatic G7731A mutation in tRNA
Lys
, 
which enabled the generation of trans-mitochondrial mito-mice expressing respiration 
defects for their use as models for diseases caused by mutations in the mitochondrial 
tRNA
Lys
 gene. 
 
 
 7 
 
 
 
 
 
 
 
 
 
MATERIALS & METHODS 
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Cell lines and cell culture 
Mouse P29 cells, their subclones, mtDNA-less (0) B82 cells, and their 
trans-mitochondrial cybrid clones were grown in DMEM (Sigma-Aldrich, St. Louis, 
USA) containing 10% fetal calf serum, uridine (50 ng/ml), and pyruvate (100 ng/ml). 
Mouse ES cells (TT2-F, an XO subline established from XY TT2 cells; Riken Center 
for Developmental Biology) and trans-mitochondrial ES cybrids were cultivated on 
mitomycin-C–inactivated feeder cells derived from fetal fibroblasts in DMEM 
(Invitrogen) supplemented with 15% Knockout Serum Replacement (Invitrogen), 
non-essential amino acids (MP Biomedicals LLC), leukemia inhibitory factor (105 U/ml, 
Invitrogen), and 100 μM 2-mercaptoethanol (Sigma–Aldrich).  
 
Cloning and sequencing of PCR products  
Total DNA extracted from P29 cells was used as the template for PCR amplifications, 
which generated two mtDNA fragments, F1 and F2, by using unique primer pairs that 
were designed to generate 2.6- and 2.7-kb fragments, respectively. The sequences of the 
primers were based on the standard mtDNA sequence of B6 mice (GenBank accession 
no., AY172335): F1 forward, nucleotides 2045–2064; F1 reverse, 4623–4603; F2 
forward, 5931–5950; and F2 reverse, 8626–8606 (Fig. 1). All PCR amplifications were 
performed in 50 l of solution consisting of PCR buffer, 0.2 mM dNTPs, 0.6 mM 
primers, 1 U AmpliTaq Gold DNA polymerase (Perkin-Elmer Applied Biosystems), 
and 1 g of cellular DNA as template. Reaction conditions were 95 ºC for 10 min, 
followed by 35 cycles of 60 s at 95 ºC, 60 s at 50–56 ºC, and 150 s at 72 ºC. PCR 
products were ligated into pUC118 (Takara) and then introduced into DH5 cells 
(Takara). Sequence templates were prepared by using a TempliPhi DNA Sequencing 
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Template Amplification Kit (Amersham Pharmacia Biosciences) according to the 
manufacturer’s protocol. Sequence reactions were performed by using dye termination 
methods (Takara PCR Thermal Cycler GP), and samples were sequenced on a 
MegaBACE1000 automated sequencer (Amersham Pharmacia Biosciences). 
 
Genotyping of mtDNA  
To detect the T7728C mutation, a 71-bp fragment containing the 7728 site was 
PCR-amplified by using the nucleotide sequences 7703 to 7723 
(5′-TATGAAGCTAAGAGCGgaAAC-3′, small letters indicate mismatch) and 7773 to 
7754 (5′-TGTGGCATATCACTATGGAG-3′) as oligonucleotide primers. Combination 
of the PCR-generated mutation with the T7728C mutation creates a restriction site for 
XmnI and generates 50- and 21-bp fragments on XmnI digestion of the PCR products. 
To detect the G7731A mutation, a 130-bp fragment containing the 7731 site was 
PCR-amplified by using the nucleotide sequences from 7633 to 7653 
(5′-GCCCATTGTCCTAGAAATGGT-3′) and 7762 to 7732 
(5′-ACTATGGAGATTTTAAGGTCTCTAACTTTAA-3′) as oligonucleotide primers. 
The G7731A mutation creates a restriction site for DraI and generates 96- and 34-bp 
fragments on DraI digestion of PCR products. The restriction fragments were separated 
by electrophoresis in a 3% agarose gel. For quantification of G7731A mtDNA, I used 
ImageJ (Rasband WS, Image J, US National Institutes of Health, Bethesda, Maryland, 
USA, http://imagej.nih.gov/ij/, 1997–2014) software. 
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Isolation of B82mt7731 cybrids  
I used mtDNA-less (0) B82 cells as recipients for G7731A mtDNA. 0 B82 cells are 
resistant to BrdU and sensitive to hypoxanthine–aminopterin–thymidine (HAT) due to 
their deficiency of thymidine kinase activity. Furthermore, 0 B82 cells are unable to 
grow in the absence of uridine and pyruvate due to their absence of mtDNA. mtDNA 
donor P29-69-183 cells were pretreated with cytochalasin B (10 μg/ml) for 10 min and 
centrifuged at 7,500 × g for 10 min at 37 °C for enucleation; the resultant cytoplasts 
were fused with 0 B82 cells by using polyethylene glycol. The fusion mixture was 
cultured in selection medium containing 5-bromodeoxyuridine (BrdU; 30 µg/ml) and 
lacking uridine and pyruvate. The selection medium excluded unenucleated P29-69-183 
cells and unfused 0 B82 cells and thus allowed exclusive growth of 
trans-mitochondrial B82mt7731 cybrids. 
 
Isolation of ESmt7731 cybrids  
Host ES cells were pretreated with rhodamine 6G (R6G; 0.38–1.5 μg/ml in 3% ethanol) 
for 48 h to eliminate endogenous mitochondria and mtDNA (10, 11). The ES cells then 
were washed with PBS and suspended in R6G-free medium for 2 h to allow recovery. 
mtDNA donor B82mt7731 cybrids were pretreated with cytochalasin B (10 μg/ml) for 
10 min and centrifuged at 22,500 × g for 30 min at 37 °C for enucleation. The resultant 
cytoplasts were fused with R6G-pretreated ES cells by using polyethylene glycol, and 
the fusion mixture was cultured in selection medium containing HAT to exclude 
unenucleated B82mt7731 cybrids. At 7 days after fusion, growing colonies were 
harvested for mtDNA genotyping. Under these selection conditions, ES cells containing 
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recovered endogenous mtDNA were not eliminated completely, owing to insufficient 
R6G treatment. 
 
Generation of chimeric mice and mito-mice-tRNA
Lys7731
  
Frozen 8-cell-stage embryos of ICR mice (ARK Resource Company) were thawed, and 
their zona pellucidae were removed by treatment with acidified Tyrode’s buffer 
(Sigma–Aldrich). Each treated embryo was placed with about 50 ESmt7731 cybrids in a 
well of a 35-mm culture dish and incubated overnight to enable aggregation. The next 
day, the embryos were transferred into pseudopregnant ICR female mice (Japan SLC). 
The resulting progeny were identified by their coat-color chimerism. Founder (F0) 
chimeric female mice were mated with C57BL/6 J (B6; CLEA Japan) male mice to 
produce the F1 generation, and F1 female mice with G7731A mtDNA in their tails (F1 
female mito-mice-tRNA
Lys7731
) were backcrossed with B6 male mice to obtain F2 
mito-mice-tRNA
Lys7731
.  
 
Mice  
Inbred B6 mice generated through more than 40 rounds of brother–sister mating were 
obtained from CLEA Japan. I maintained mito-mice-tRNA
Lys7731
 by repeated 
backcrossing of these female mice with B6 male mice. Animal experiments were 
performed in accordance with protocols approved by the Experimental Animal 
Committee of the University of Tsukuba, Japan.  
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Oxygen consumption 
Cells were washed once in PBS and then resuspended in PBS at a density of 4 × 10
6
 
cells/ml. Oxygen consumption was measured by using an oxygraph equipped with a 
Clark-type electrode (model 5300, Yellow Springs Instruments Company) at 37 °C. The 
cell suspension (2 ml) was transferred to a polarographic cell, and basal respiration was 
measured immediately under constant stirring. 
 
Measurement of reactive oxygen species in mitochondria 
Reactive oxygen species were detected by using the mitochondrial superoxide indicator 
MitoSOX-Red (Invitrogen). Cells were incubated with 1 µM MitoSOX-Red for 15 min 
at 37 °C in PBS, washed twice with PBS, and then immediately analyzed by using flow 
cytometry (FACScan, Becton Dickinson). 
 
Histopathologic analyses 
Formalin-fixed, paraffin-embedded sections (thickness, 5 µm) were stained with 
hematoxylin and eosin (H&E) to identify features characteristic of renal failures. 
Cryosections (thickness, 10 µm) of skeletal muscle were stained with modified Gomori 
trichrome for histopathologic analysis to identify RRFs. Cryosections (thickness, 10 
µm) of renal tissues were prepared, and histologic analyses of cytochrome c oxidase 
(COX) and succinate dehydrogenase (SDH) activities were performed as described 
previously (12). 
 
 13 
 
Grip strength test 
Muscle strength was estimated by using a Grip Strength Meter (Columbus Instruments); 
three sequential trials were performed on each mouse. 
 
Biochemical measurements of respiratory enzyme activity 
Mitochondrial respiratory complex I (NADH dehydrogenase), complex II (succinate 
dehydrogenase), and complex III (cytochrome c reductase) are components of the 
electron-transport chain and are located in the mitochondrial inner membrane. The 
activity of these enzymes was assayed as described previously (13). Briefly, to estimate 
the activity due to complex I + III, NADH and cytochrome c (oxidized form) were used 
as substrates, and the reduction in cytochrome c was monitored by measuring 
absorbance at a wavelength of 550 nm. To estimate the activity due to complex II + III, 
sodium succinate and cytochrome c (oxidized form) were used as substrates, and the 
reduction of cytochrome c was monitored as described previously.  
 
Measurement of blood glucose, lactate, and blood urea nitrogen (BUN) 
To determine fasting blood lactate and glucose concentrations, peripheral blood was 
collected from the tail veins of mice after overnight fasting from food. After oral 
administration of glucose (1.5 g/kg body weight), blood was collected again, and lactate 
and glucose concentrations were measured by using an automatic blood lactate test 
meter (Lactate Pro; Arkray) and glucose test meter (Dexter ZII; Bayer), respectively. 
BUN was measured by using a Urea N B test (Wako Pure Chemical, Osaka, Japan) in 
accordance with the manufacturer's protocol. 
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Measurement of hematocrit 
To determine hematocrit, capillary blood samples were obtained from each mouse by 
using heparinized capillary tubes, which then were centrifuged at 10,500 × g for 5 min. 
Packed cell volumes were measured by using a hematocrit reader. 
 
Sequence analysis 
Each DNA (3 µg) extracted from P29-69-183 cells and from kidney of 
mito-mouse-tRNA
Lys7731
 were used to prepare the sequencing libraries. These 
sequencing libraries were constructed by using the TruSeq DNA LT Sample Prep Kit 
(Illumina) according to the instructions in TruSeq DNA Sample Preparation Guide Rev. 
C (Illumina). These DNA samples were sheared by using an acoustic solubilizer 
(Covaris), and the overhangs resulting from the fragmentation were converted to blunt 
ends by phosphorylation of the DNA fragments. The blunt fragments were adenylated at 
their 3’ ends were ligated to the ends of the DNA fragments, which were subsequently 
enriched by PCR. Clonal template clusters were generated from the sequencing library, 
and sequencing was performed by the reversible terminator-based method (14). Base 
calling and data conversion into Fastq files were performed by using software providing 
the Burrows-Wheeler Alignment Tool (15). 
 
Statistical analysis 
Data are presented as mean ± SD and were analysed by using Student’s t test or Tukey 
honestly significant difference test; P values less than 0.05 were considered significant. 
Excel (Microsoft) software was used for Student’s t test and ANOVA, and R (The R 
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Foundation for Statistical Computing, http://www.R-project.org.)(16) was used for 
Tukey honestly significant difference test. 
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RESULTS 
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Cloning and sequence analysis of PCR products including tRNA genes 
To detect small proportion of mtDNA with somatic and possibly pathogenic 
mutations in the tRNA
Leu(UUR)
 and tRNA
Lys
 genes, I used two sets of primers so that the 
resulting PCR products would include the tRNA
Leu(UUR)
 or tRNA
Lys
 gene of P29 cells (Fig. 
1). After cloning the PCR products, I sequenced all 43 clones obtained and compared 
the resulting sequences with that of mtDNA from P29 cells (Table 1). I found one and 
two somatic mutations in the mitochondrial tRNA
Leu(UUR)
 and tRNA
Lys
 genes, 
respectively. Given that each somatic mutation was present in only one of the 43 clones, 
the proportion of each in the mtDNA population of P29 cells would be about 2.2%.  
The T7728C and G7731A mutations in the tRNA
Lys
 gene both occurred in 
conserved sites (Table 2) and may correspond to pathogenic mutations that induce 
respiration defects by their accumulation. Moreover, an orthologous mutation to mouse 
G7731A has been reported to occur in human mtDNA from patients with mitochondrial 
diseases (17, 18).  
Therefore, I selected these mutations in mtDNA for the generation of 
mito-mice. In an attempt to detect the T7728C and G7731A mutations in P29 mtDNA, I 
performed XmnI and DraI digestions of the PCR products of mtDNA, because the 
T7728C and G7731A mutations create an XmnI site and a DraI site, respectively (see 
MATERIALS & METHODS). However, the T7728C and G7731A mutations were 
undetectable due to their insufficient amounts in P29 cells.  
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Concentration of G7731A mtDNA in subclones of P29 cells 
Previous study showed that two mtDNA haplotypes with different mutations in 
single cells segregate stochastically during cell division (19). Therefore, some 
individual cells in the P29 population may possess detectable amounts of the mutated 
mtDNA. To obtain some individual cells that had accumulated either T7728C mtDNA 
or G7731A mtDNA from the P29 cell population, I isolated 100 subclones from P29 
cells. Their mtDNA genotyping showed that two subclones, P29-42 and P29-69, 
possessed 34% and 48% G7731A mtDNA, respectively. However, I did not obtain any 
subclones carrying detectable amounts of T7728C mtDNA. 
In the case of human mitochondrial tRNA gene mutations found in patients 
with mitochondrial diseases, respiration defects were apparent only when the mutated 
mtDNA had accumulated to more than 90% (20). To isolate P29 cells with more than 
90% G7731A mtDNA, I cultured subclone P29-69, which had 48% G7731A mtDNA, 
for additional 3 months to allow further amplification of G7731A mtDNA through 
stochastic segregation; I then isolated more than 200 subclones from the P29-69 cells. I 
obtained one subclone, P29-69-183, which contained 92% G7731A mtDNA (Fig. 
2A)—a level likely to be sufficient for the expression of respiration defects, if the 
G7731A mutation indeed is a pathogenic mutation.  
Determination of the pathogenicity of G7731A mtDNA  
Comparison of the O2 consumption rates between parental P29 cells and the 
P29-69-183 cells revealed the expression of respiration defects in the P29-69-183 cells 
(Fig. 2B). Moreover, P29-69-183 cells demonstrated slight overproduction of reactive 
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oxygen species (Fig. 2C), indicating the pathogenicity of the G7731A mutation. 
Whole-sequence analysis of mtDNA in P29-69-183 cells showed that the G7731A 
mutation is the only mutation in those cells that is capable of inducing respiration 
defects (Table 3). However, I had to resolve two important issues before generation of 
the mito-mice carrying G7731A mtDNA.  
First, I had to confirm that the respiration defects in P29-69-183 cells were due 
to G7731A mtDNA and not to the selection of cells with mutations in nuclear DNA that 
were acquired during repeated recloning. Second, P29-69-183 cells could not be used as 
mtDNA donors to isolate mouse ES cells with G7731A mtDNA because of the 
difficulty of excluding unenucleated P29-69-183 cells from fusion mixtures of ES and 
enucleated P29-69-183 cells.  
To simultaneously resolve these issues, I cytoplasmically transferred G7731A 
mtDNA from P29-69-183 cells into mtDNA-less (0) B82 cells (6). B82 cells are mouse 
fibrosarcoma cells that are resistant to 5-bromodeoxyuridine (BrdU) and sensitive to 
hypoxanthine–aminopterin–thymidine (HAT) due to their deficiency of thymidine 
kinase activity (6). Moreover, 0 B82 cells are unable to grow in the absence of uridine 
and pyruvate due to their complete lack of mtDNA. Using selection medium containing 
BrdU and lacking uridine and pyruvate, I isolated two colonies, B82mt7731-1 and -2. 
Genotyping of mtDNA showed that B82mt7731-1 and -2 possessed 70% and 95% 
G7731A mtDNA, respectively (Fig. 3A), indicating the transfer of G7731A mtDNA 
from P29-69-183 cells into 0 B82 cells.  
I then examined the respiratory function of these 2 cybrids by estimating O2 
consumption rates and the amounts of reactive oxygen species. The B82mt7731-2 
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cybrids showed decreased O2 consumption rates (Fig. 3B) and increased production of 
reactive oxygen species (Fig. 3C) compared with those of B82mtB6 cybrids containing 
normal mtDNA from B6 mice. Therefore, respiration defects were transferred to 
B82mt7731 cybrids concurrently with the transfer of G7731A mtDNA from 
P29-69-183 cells into 0 B82 cells, suggesting that the somatic G7731A mutation in 
mtDNA is a pathogenic mutation that can induce mitochondrial respiration defects by 
its predominant accumulation. Furthermore, B82mt7731 cybrids are effective as donors 
of G7731A mtDNA to ES cells, because unenucleated B82mt7731 cybrids can be 
excluded by using selection medium containing HAT. 
Isolation of ES cells containing G7731A mtDNA and their chimeric mice 
Previous study showed that no chimeric mice were obtained from ES cells 
carrying predominant amounts of ΔmtDNA, because the significant respiration defects 
induced by ΔmtDNA inhibited differentiation of ES cells to various tissues and germ 
cells (21). Therefore, I was concerned that the transfer of mtDNA from B82mt7731-2 
cybrids containing 95% G7731A mtDNA to ES cells would inhibit generation of 
chimeric mice, and instead used B82mt7731-1 cybrids containing lower proportions of 
G7731A mtDNA (Fig. 3A) as mtDNA donors.  
Female (XO)-type ES cells (TT2 cells) were pretreated with rhodamine 6G 
(R6G) to eliminate endogenous mitochondria and mtDNA. They then were used as 
recipients of G7731A mtDNA and fused with enucleated B82mt7731-1 cybrids. The 
fusion mixture was cultured in selection medium containing HAT to exclude 
unenucleated B82mt7731-1 cybrids. Seven ES clones grew in the selective medium, 
two of which—clones ESmt7731-4 and -7—contained G7731A mtDNA (Fig. 4). The 
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absence of G7731A mtDNA in the remaining five clones may be due to incomplete 
elimination of endogenous mtDNA in ES cells during R6G pretreatment.  
I then aggregated the ESmt7731-4 and -7 cybrid clones with 8-cell-stage mouse 
embryos (ICR strain) and obtained 35 F0 chimeric mice. Because mouse mtDNA is 
inherited strictly maternally (22, 23), I selected 15 F0 chimeric female mice with 
13%–76% G13997A mtDNA in their tails as founder mice (Table 4) and mated them 
with B6 male mice to generate F1 mice that carried G7731A mtDNA due to its transfer 
through the female germline.  
Generation of mito-mice-tRNA
Lys7731
 via female germ line transfer of G7731A mtDNA 
Of the 15 F0 female chimeras, 11 produced a total of 121 F1 pups, 63 of which 
had G7731A mtDNA in their tails (Table 4). This finding suggests that G7731A 
mtDNA was transmitted maternally from F0 female mice to F1 progeny. Mice that 
carried G7731A mtDNA derived from lung carcinoma P29 cells were named 
‘mito-mice-tRNALys7731’.  
Of the 63 F1 mice with G7731A mtDNA in their tails, seven F1 female mice 
carrying high proportions of G7731A mtDNA were mated with B6 male mice to obtain 
subsequent generations (F2-F5) of mito-mice-tRNA
Lys7731
 with sufficient G7731A 
mtDNA for the expression of respiration defects and resultant disorders. The 
proportions of G7731A mtDNA varied significantly among the pups born to each dam, 
but none of the pups carried more than 85% G7731A mtDNA (Fig. 5A). 
To examine the reasons for the lack of mito-mice-tRNA
Lys7731
 with more than 
85% G7731A mtDNA, I estimated the proportion of G7731A mtDNA in the oocytes 
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obtained by ovarian hyperstimulation of F5 female mito-mice-tRNA
Lys7731
 with high 
proportions of G7731A mtDNA. The results again showed significant variation in 
G7731A mtDNA proportions among the oocytes and the absence of the oocytes with 
more than 85% G7731A mtDNA (Fig. 5B), indicating that lethality of oocytes with high 
levels of G7731A mtDNA is responsible for the absence of mito-mice-tRNA
Lys7731
 
carrying more than 85% G7731A mtDNA. 
My observations suggest that mito-mice-tRNA
Lys7731
 at least in part can serve 
as models to investigate pathogenesis of mitochondrial diseases that arise due to 
mutations in the mitochondrial tRNA genes. In addition, the transmission profiles of 
G7731A mtDNA showed that selecting oocytes with lower levels of the mutated 
mtDNA likely would be effective to prevent maternal transmission of the disease 
phenotypes to the progeny. 
Expression of disorders in mito-mice-tRNA
Lys7731
 with predominant G7731A mtDNA 
I used B6 mice as controls and three groups of F5 young (4-months-old) 
mito-mice-tRNA
Lys7731
 with different heteroplasmic conditions (low, intermediate, and 
high levels of G7731A mtDNA) in their tails to examine various phenotypes relevant to 
mitochondrial diseases (Fig. 6). 
First, I analyzed body length (Fig. 6A) and muscle strength (Fig. 6B), because 
abnormalities in these characteristics frequently occur in patients with mitochondrial 
diseases (17, 18), and these parameters can be examined without euthanizing the young 
mice. Unlike mito-mice-tRNA
Lys7731
 with low and intermediate levels, those with high 
levels of G7731A mtDNA showed short body length (Fig. 6A) and muscle weakness 
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(Fig. 6B), which are closely associated with the clinical phenotypes caused by 
mutations in the mitochondrial tRNA
Lys
 gene (2, 17, 18). 
I then quantitatively estimated mitochondrial respiratory function and revealed 
respiration defects in skeletal muscle and kidney from mito-mice-tRNA
Lys7731
 with high 
levels of G7731A mtDNA (Fig. 6C).
 
Therefore, accumulation of G7731A mtDNA 
likely is responsible for the respiration defects in mito-mice-tRNA
Lys7731
 with high 
levels of G7731A mtDNA (Fig. 6C). These respiration defects in the skeletal muscle 
subsequently result in the expression of muscle weakness (Fig. 6B), which corresponds 
to a phenotype relevant to mitochondrial diseases (2). 
In contrast, other metabolic parameters relevant to mitochondrial diseases were 
normal in young mito-mice-tRNA
Lys7731
 (Fig. 7). Histochemical analysis showed that 
ragged-red fibers (RRF) frequently observed in MERRF patients (2) and renal failures 
frequently observed in mito-mice-Δ (4, 5) were not found in young 
mito-mice-tRNA
Lys7731
 (Figs. 8 and 9). Absence of these disorders in 
mito-mice-tRNA
Lys7731
 may be due in part to that G7731A mtDNA proportions in them 
were not sufficient to induce significant respiration defects. For example, G8344A 
mtDNA proportions exceed 85% in patients with MERRF (2). My failure to obtain 
mito-mice-tRNA
Lys7731
 with more than 85% G7731A mtDNA can be explained by the 
lethality of mouse oocytes carrying these levels of G7731A mtDNA (Fig. 5B).  
Late-onset metabolic abnormalities in aged mito-mice-tRNA
Lys7731
  
I then used aged (26-month-old) male mito-mice-tRNA
Lys7731
 with low (< 5%) 
or high (70% to 75%) levels of G7731A mtDNA in their tails at 4 weeks after birth and 
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age- and sex-matched B6 mice (negative controls). First, I evaluated body length (Fig. 
10A) and muscle strength (Fig. 10B), because abnormalities in these phenotypes are 
expressed in young (4-month-old) mito-mice-tRNA
Lys7731
 (Fig. 6A and B) and can be 
examined without killing the mice. Short body length (Fig. 10A) and muscle weakness 
(Fig. 10B), which are closely associated with the clinical abnormalities caused by the 
orthologous G8328A mutation in the human mitochondrial tRNA
Lys
 gene (17, 18), 
occurred exclusively in young mito-mice-tRNA
Lys7731
 with high levels of G7731A 
mtDNA 
I then examined various metabolic parameters relevant to mitochondrial 
diseases. Whereas these features were normal in young mito-mice-tRNA
Lys7731
 (Fig. 7), 
I expected that abnormalities in these parameters would be expressed as late-onset 
disorders as the mito-mice-tRNA
Lys7731
 aged. Unlike aged B6 mice and aged 
mito-mice-tRNA
Lys7731
 with low levels of G7731A mtDNA, aged 
mito-mice-tRNA
Lys7731
 with high levels of G7731A mtDNA exclusively had low 
hematocrit values (Fig. 10C), lactic acidosis (Fig. 10D), and increased levels of BUN in 
the peripheral blood (Fig. 10E). In contrast, although patients with mitochondrial 
diseases sometimes demonstrate mitochondrial diabetes (1–3), neither group of aged 
mito-mice-tRNA
Lys7731
 manifested hyperglycemia (Fig. 10F). Therefore, except for 
hyperglycemia, the metabolic abnormalities seen in patients with mitochondrial diseases 
were expressed as late-onset disorders in aged mito-mice-tRNA
Lys7731
 with high levels 
of G7731A mtDNA. 
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Lifespan and tissue abnormalities in euthanized moribund mito-mice-tRNA
Lys7731
  
I then assessed the lifespans of mito-mice-tRNA
Lys7731
 and the tissue 
abnormalities in euthanized moribund mice. The median survival times in B6 mice and 
in mito-mice-tRNA
Lys7731
 with low or high levels of G7731A mtDNA were 26, 28, and 
27 months, respectively (Fig. 11). Thus, median survival times did not differ 
significantly between mito-mice-tRNA
Lys7731
 with high and low levels of G7731A 
mtDNA. 
Gross necropsy of euthanized moribund mice showed that muscle atrophy (Fig. 
12A) and anemic kidneys (Fig. 13A) occurred exclusively in mito-mice-tRNA
Lys7731
 
with high levels of G7731A mtDNA. Muscle atrophy occurs not only in elderly men 
and women (45) and patients with mitochondrial diseases (46) but also in mtDNA 
mutator mice (47, 48) and mito-mice-Δ that express significant respiration defects (49). 
Moreover, renal abnormalities have been reported to occur occasionally in patients with 
mitochondrial diseases (50–52) and in mito-mice-Δ that express significant respiration 
defects (4, 5). 
I then histologically analyzed these tissues to characterize the macroscopic 
abnormalities in greater detail. First, I used modified Gomori trichrome staining to 
reveal RRFs that occur frequently in patients with mitochondrial diseases (2). However, 
even aged mito-mice-tRNA
Lys7731
 with high levels of G7731A mtDNA lacked RRFs in 
skeletal muscle (Fig. 12B); this was consistent with recent findings in mtDNA mutator 
mice and mito-mice-Δ (49). 
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Although the skeletal muscle was histologically normal, the anemic kidneys 
demonstrated multiple abnormalities. The renal cortical tubules of aged 
mito-mice-tRNA
Lys7731
 with high levels of G7731A mtDNA were dilated and contained 
casts; these changes, indicative of renal failures, did not occur in aged B6 mice or in 
aged mito-mice-tRNA
Lys7731
 with low levels of mutated mtDNA (Fig. 13B). Given that 
young mito-mice-tRNA
Lys7731
 lacked similar renal changes (Fig. 9), these changes 
correspond to a late-onset disorder. Histologic analysis of mitochondrial respiratory 
function revealed decreased mitochondrial COX activity in the kidney tissue of aged 
mito-mice-tRNA
Lys7731
 with high levels of G7731A mtDNA (Fig. 13C). Therefore, the 
respiration defects in mito-mice-tRNA
Lys7731
 with high levels of G7731A mtDNA (Fig. 
13C) likely caused their renal failures (Fig. 13B).  
Genotyping of G7731A mtDNA in tissues of mito-mice-tRNA
Lys7731
 
For the purposes of this study, I classified 4-week-old mito-mice-tRNA
Lys7731
 
as having low or high amounts of mutated mtDNA by estimating the proportions of 
G7731A mtDNA isolated from samples of tail tissue. The question that then arises is 
whether the proportions of G7731A mtDNA differ among tissues or with age.  
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DISCUSSION 
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The current study generated mito-mice-tRNA
Lys7731
 carrying G7731A mtDNA 
with a pathogenic G7731A mutation in the mitochondrial tRNA
Lys
 gene. Specifically, I 
concentrated a small proportion of mtDNA with a somatic G7731A mutation that was 
present in P29 cells and then introduced it into ES cells to generate 
mito-mice-tRNA
Lys7731
. The resulting mice were used to investigate the pathogenesis 
and transmission profiles of G7731A mtDNA. 
Regarding the pathogenesis of G7731A mtDNA, young mito-mice-tRNA
Lys7731
 
with 74%-84% G7731A mtDNA demonstrated respiration defects and the resultant 
muscle weakness and short body length (Fig. 6). These abnormalities in these mice are 
very similar to those found in patients with mitochondrial diseases due to human 
orthologous G8328A mutation (17, 18) and in MERRF patients carrying the G8344A 
mutation in the tRNA
Lys
 gene (2, 24–26). Although these abnormalities were expressed 
in mito-mice-tRNA
Lys7731
 with 74%-84% G7731A mtDNA (Fig. 6) and in the patients 
with 57% (17) and 82% G8328A mtDNA (18), more than 85% G8344A mtDNA was 
required for the onset of severe abnormalities in patients with MERRF (2, 24–26). 
However, I could not obtain mito-mice-tRNA
Lys7731
 with more than 85% G7731A 
mtDNA (Fig. 5A), which would be expected to induce significant respiration defects 
and severe abnormalities corresponding to MERRF, owing to the lethality of mouse 
oocytes with more than 85% G7731A mtDNA (Fig. 5B). Therefore, the expression of 
the significant respiration defects and severe clinical disorders in MERRF patients can 
be explained by supposing the absence of lethality in human oocytes even at G8344A 
mtDNA levels exceeding 85%. In contrast, previous studies (4, 5) showed that 
mito-mice-Δ possessed more than 85% ΔmtDNA with a large-scale deletion, and 
expressed significant respiration defects and severe abnormalities, even though their 
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oocytes did not have more than 80% ΔmtDNA (27). The increase in the proportion of 
ΔmtDNA after birth may be due to its replication advantage (4, 5).  
The absence of abnormalities in mito-mice-tRNA
Lys7731
 with intermediate 
levels (37%-56%) of G7731A mtDNA (Fig. 6A and B) appears to be different from 
what is observed for mtDNA with human orthologous G8328A mutation, because the 
patient with only 57% G8328A mtDNA in the skeletal muscles expressed disorders (17). 
This apparent discrepancy may be due to the aging effects in the patient with 57% 
G8328A mtDNA, considering that the phenotypes of the mito-mice-tRNA
Lys7731
 were 
examined 4 months after the birth (Fig. 6), and that the patient expressed disorders 45 
years after the birth (17). Thus, I have to examine whether mito-mice-tRNA
Lys7731
 with 
intermediate levels of G7731A mtDNA express abnormalities along with their aging. 
Regarding transmission profiles, those of mito-mice-tRNA
Lys7731
 are highly 
similar to those of MERRF patients, in that the mutated mtDNA is inherited to 
subsequent generations through the female germline, and the proportion of mutated 
mtDNA varied markedly among the pups born to each dam (Fig. 5A). The pups always 
carry wild-type mtDNA (Fig. 5A), due to the significant pathogenicity of G7731A 
mtDNA and resultant induction of oocyte lethality in the absence of wild-type mtDNA 
(Fig. 5B). In contrast, previously generated mito-mice-COI
6589
 (6) and 
mito-mice-ND6
13997
 (7, 8), which carry a 100% (homoplasmic) T6589C mtDNA 
mutation and a homoplasmic G13997A mtDNA mutation in the structural genes COXI 
and ND6, respectively, due to the mild pathogenicity of the mutations. Because patients 
with MERRF and mito-mice-tRNA
Lys7731
 always carry both wild-type mtDNA and 
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mutated mtDNA, mito-mice-tRNA
Lys7731
 are appropriate models for further 
investigating the transmission profiles of mutated mtDNA with marked pathogenicity. 
The heteroplasmic mtDNA (wild-type mtDNA and mutated G7731A mtDNA) 
of these mito-mice-tRNA
Lys7731
 segregated stochastically, like those derived from 
different mouse strains (BALB and NZB) with polymorphic mutations (28) and those 
with and without point mutations (29). The significant variation in the G7731A mtDNA 
proportions among pups (Fig. 5A) may reflect ‘bottleneck effects’ with (30, 31) or 
without decrease in the mtDNA copy number (32, 33) during female germline 
transmission of the heteroplasmic mtDNAs.  
Regarding primary prevention of mitochondrial diseases, the results in Figs. 5 
and 6 indicate that the selection of oocytes with low proportions of G7731A mtDNA 
likely would yield phenotypically normal mice. In contrast, previous study (27) showed 
that nuclear transplantation from zygotes of trans-mitochondrial mito-mice-Δ into 
enucleated zygotes with normal mtDNA is effective as germline gene therapy. Many 
recent reports similarly have noted that the use of the nuclear transplantation from 
human oocytes of affected mothers into enucleated oocytes donated by unrelated 
women would prevent the transmission of mitochondrial diseases caused by mtDNA 
mutations to their children (34–36). However, this technology includes the risk of 
inducing nuclear abnormalities, even though it excludes the risk of mitochondrial 
abnormalities. This problem would be resolved by the selection of oocytes with low 
proportions of mutated mtDNA. Previous study showed that polar bodies are effective 
for preimplantation genetic diagnosis (PGD) to deduce the proportion of mutated 
mtDNA in mouse oocytes (27). However, subsequent studies using polar bodies from 
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human oocytes (37) and blastomeres from human embryos (38, 39) indicated that 
blastomeres are more appropriate than the polar bodies for PGD to deduce the 
proportion of mutated mtDNA. Although this procedure would not completely exclude 
the mutated mtDNA from the affected mothers, previous studies (40, 41) showed the 
presence of inter-mitochondrial complementation to maintain normal respiratory 
function in the presence of the mutated mtDNA. Therefore, in light of the results in Figs. 
5 and 6, I propose that the selection of embryos with low proportions of mutated 
mtDNA from affected mothers by diagnosing the blastomeres would be effective for 
obtaining unaffected children. 
Using mito-mice-tRNA
Lys7731
, I showed that high levels of G7731A mtDNA 
and the resultant respiration defects did not affect median survival times (Fig. 11), even 
though they induced the late-onset disorders (Figs. 10, 12 and 13). In contrast, 
accumulation of pathogenic mutations in human mtDNA and the resultant respiration 
defects have been proposed to be responsible for features of normal aging as well as of 
mitochondrial diseases (1–3). However, current observations suggest that mtDNA with 
pathogenic mutations is not necessarily associated with aging processes. This idea is 
further supported by previous findings that mito-mice-COI
6589
, which contain mtDNA 
with a T6589C mutation in COI, and mito-mice-ND6
13997
, which carry mtDNA with a 
G13997A mutation in ND6, had normal lifespans (8).  
In contrast, these mito-mice-tRNA
Lys7731
 developed several phenotypes 
relevant to mitochondrial diseases, including anemia (Fig. 10C), lactic acidosis (Fig. 
10D), and increased BUN (Fig. 10E). Moreover, euthanized moribund 
mito-mice-tRNA
Lys7731
 showed muscle atrophy (Fig. 13A) and renal failures (Fig. 13). 
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The muscle atrophy in aged mito-mice-tRNA
Lys7731
 with high levels of G7731A mtDNA 
(Figs. 12A) likely is associated with their muscle weakness (Fig. 10B). It is also likely 
that the anemic kidney tissue in the aged mito-mice-tRNA
Lys7731
 (Fig. 13A) reflects their 
low hematocrit levels (Fig. 10C). Moreover, the increased BUN values (Fig. 10E) likely 
reflect the renal failures (Fig. 13B) caused by high levels of G7731A mtDNA and the 
resultant respiration defects (Fig. 13C). Given that mito-mice-tRNA
Lys7731
 with low and 
high levels of G7731A mtDNA have the same B6 nuclear genetic background, the 
respiration defects induced exclusively by the high levels of G7731A mtDNA are 
responsible for the development of these late-onset disorders.  
A question that then arises is why these abnormalities have a late onset in 
mito-mice-tRNA
Lys7731
. One explanation is the requirement of long-term exposure of the 
tissues to respiration defects or the requirement of age-dependent development of 
nuclear abnormalities for the onset of these disorders. It is also likely that each cell in a 
tissue eventually contains solely mtDNA either with or without the G7731A mutation as 
a consequence of stochastic segregation over time (19, 28 29), resulting in the induction 
of the late-onset disorders due to the apoptosis or substantial dysfunction of cells 
containing only G7731A mtDNA. 
In contrast to their other clinically characteristic features, aged 
mito-mice-tRNA
Lys7731
 with high levels of G7731A mtDNA did not demonstrate 
peripheral hyperglycemia (Fig. 10F) indicative of mitochondrial diabetes; this disorder 
has been proposed to occur frequently in patients with mitochondrial diseases (1–3). 
However, these results are consistent with previous findings in mito-mice-COI
6589
, 
which have normal blood glucose levels (6). In addition, blood glucose levels were low 
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in mito-mice-Δ (53) but high in mito-mice-ND613997 (8), indicating that high levels of 
pathogenic mtDNA mutations and the resultant respiration defects do not necessarily 
cause mitochondrial diabetes.  
Current study also showed that all groups of these mice—even aged 
mito-mice-tRNA
Lys7731
 with high levels of G7731A mtDNA (that is, 70% to 
75%)—lacked RRFs (Fig. 12B). The absence of RRFs may be due in part to the fact 
that the amount of G7731A mtDNA was insufficient to induce RRFs. Thus, somehow 
mito-mice-tRNA
Lys7731
 with more than 75% G7731A mtDNA have to be generated for 
RRF development. However, the death of B6 mouse oocytes that carry levels of 
G7731A mtDNA in excess of 85% (Fig. 5) would prevent the generation of 
mito-mice-tRNA
Lys7731
 with sufficient proportions of G7731A mtDNA to develop RRFs. 
It is likely that some as-yet unknown nuclear factors in mouse strains other than B6 may 
allow the survival of oocytes with more than 85% G7731A mtDNA.  
To evaluate this idea, I plan to replace the B6 nuclear genetic background of 
mito-mice-tRNA
Lys7731
 with that from other strains. This replacement may support the 
survival of oocytes with more than 85% G7731A mtDNA and subsequently the 
development of skeletal muscle RRFs and peripheral hyperglycemia in the resultant 
mito-mice-tRNA
Lys7731
. 
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Table 1  
Somatic mutations in P29 mtDNA according to cloning and sequence 
analysis of the PCR products including the tRNALeu(UUR) and tRNALys genes 
* Registered under the GenBank accession number EU312160. 
† The T7728C mutation in the tRNALys gene occurred in a site highly conserved 
throughout animals and fungi (see Table 3). The mutation affects the first base of 
an anticodon triplet (TTT), resulting in an anticodon swap from TTT to CTT (Lys 
to Glu). 
‡ The mutation equivalent to the G7731A mutation in the tRNALys gene of mice 
has been reported to occur in the mtDNA from human patients with 
mitochondrial diseases (17, 18). 
No. of 
clones 
tRNA genes LeuUUR Ile Met SerCUN Lys Lys 
nucleotide 
position 
2721 3760 3883 6931 7728† 7731‡ 
P29 sequence* T G - T T G 
1   del - - - - - 
1  - A - - - - 
1  - - insA - - - 
1  - - - C - - 
1  - - - - C - 
1  - - - - - A 
37   - - - - - - 
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Table 2  
Comparison of mutations in the mouse mitochondrial tRNA gene with the 
wild-type tRNA genes of other species 
 
  Leu(UUR)  Lys 
  del2721T  T7728C  G7731A 
Mutation ―  C   A  
Mouse T  T   G  
Human C  T   G  
Xenopus T  T   G  
Zebrafish C  T   G  
Drosophila T  T   A  
Nematoda ―  T   T  
Yeast C  T   G  
                
The GenBank accession numbers of the sequences used in the alignment are: 
mouse, AY172335; human, NC_012920; Xenopus, NC_001573; zebrafish, 
NC_002333; Drosophila, NC001709; Nematoda, NC_001328; yeast, 
NC_001224. 
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Table 3  
Whole-sequence analysis of the mtDNA from P29-69-183 cells 
genes tRNA
Lys
  tRNA
Arg
  D-loop 
nucleotide position 7731  9818– 9821–   16099 16105 
P29 sequence* G  (T)3 (A)9 (A)9  A T 
variant sequence A  (T)2 (A)8 (A)10  C C 
 P29-69-183** 89.6%†  16.4% 8.2% 6.5%  31.6% 47.6% 
 
mito-mouse-tRNA
Lys7731‡ 
80.0%  3.6% 0.5% 18.1%  26.9% 37.0% 
 
* P29 mtDNA sequence, GenBank accession number EU312160. 
**Registered under GenBank accession no. AP014540. 
† Whole-sequence analysis of mtDNA from P29-69-183 cells showed that they 
had 89.6% G7731A mtDNA. This value was almost equivalent to that obtained in 
Fig. 2A (92%), suggesting the reliability of my quantification of G7731A mtDNA 
proportion by using restriction fragment length polymorphism. 
‡Kidney of F5 mito-mouse-tRNA
Lys7731 possessing 81.3% G7731A mtDNA 
quantified by using restriction fragment length polymorphism was used for 
whole-sequence analysis of the mtDNA. All polymorphic mutations found in 
mtDNA of P29-69-183 cells have persisted in mtDNA of a mito-mouse-tRNA 
Lys7731. Registered under GenBank accession no. AP014541. 
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Table 4  
Generation of F0 chimeric mice and their F1 progeny that carry G7731A 
mtDNA in their tails. 
* Chimerism was judged by coat color. 
 
ES clones 
 
% G7731A  
mtDNA 
15 F0 chimeric female mice   F1 mice 
 
% Chimerism* 
 % G7731A 
mtDNA  
in tails    
No. of F1 pups with 
G7731A mtDNA / 
No. of F1 pups 
ESmt7731-4  49.8 95  68   4/4  
   95  53   2/12  
   90  45   24/24  
   50  48   0/17  
   40  16   0/0  
   35  21   0/8  
ESmt7731-7  48.8 95  72   19/19  
   95  76   4/4  
   95  72   2/12  
   95  68   8/8  
   80  52   0/8  
   60  61    0/5  
   40  26   0/0  
   15  13   0/0  
   10  19   0/0  
          Total 63/121   
 47 
 
 
 
 
 
 
 
 
 
FIGURES & LEGENDS 
 48 
 
Fig. 1 
Nucleotide positions of PCR primers on the mouse mtDNA map.  
To detect small proportions of mtDNA with somatic but possibly pathogenic 
mutations in the tRNALeu(UUR) and tRNALys genes of P29 cells, I used two sets of 
PCR primers so that the resultant PCR products included the tRNALeu(UUR) and 
tRNALys genes, respectively. These products also included five additional tRNA 
genes (tRNAIle, tRNAGln, tRNAMet, tRNASer(CUN), and tRNAAsp). 
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Fig. 2  
Characterization of P29-69-183 cells to determine the pathogenicity of a 
G7731A mutation in the mitochondrial tRNALys gene.  
(A) Estimation of the proportion of G7731A mtDNA in P29 and P29-69-183 
cells by DraI digestion of the PCR products. The G7731A mtDNA produced 
96-bp and 34-bp fragments due to the gain of a DraI site through G7731A 
substitution in the tRNALys gene, whereas mtDNA without the mutation 
produced a 130-bp fragment. Quantitative estimation of G7731A mtDNA 
showed that P29-69-183 cells contained 92% G7731A mtDNA.  
(B) Estimation of O2 consumption rates of P29 and P29-69-183 cells.   
*, P < 0.05.  
(C) Estimation of mitochondrial superoxide levels in P29 and P29-69-183 cells 
after their treatment with MitoSOX Red. **, P < 0.01. 
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Fig. 3  
Characterization of trans-mitochondrial B82mt7731 cybrids for their use as 
G7731A mtDNA donors to ES cells.  
(A) Estimation of the proportion of G7731A mtDNA in cybrids clones 
B82mt7731-1 and B82mt7731-2 by DraI digestion of the PCR products. 
Quantitative estimation of G7731A mtDNA showed that B82mt7731-1 and 
B82mt7731-2 had 70% and 95% G7731A mtDNA, respectively.  
(B) Estimation of O2 consumption rates. **, P < 0.01.  
(C) Estimation of mitochondrial superoxide levels after treatment with MitoSOX 
Red. **, P < 0.01. 
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Fig. 4  
Identification of G7731A mtDNA in ESmt7731 cybrid clones grown in 
selection medium.  
I was able to obtain two ESmt7731 cybrid clones carrying G7731A mtDNA 
(ESmt7731-4 and -7) but was unable to exclude ES cells that lacked G7731A 
mtDNA, owing to incomplete elimination of endogenous mtDNA by R6G 
treatment. Accordingly, ESmt7731-1, -2, -3, -5, and -6 correspond to ES cells 
that lacked G7731A mtDNA but contained endogenous mtDNA. 
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Fig. 5  
Variation of G7731A mtDNA proportions among pups or oocytes from 
individual female mice. 
(A) Variation of G7731A mtDNA proportions among F5 pups born to three F4 
dams. G7731A mtDNA proportions were estimated by using tails from F5 pups 
that were obtained from three F4 dams with high proportions of G7731A 
mtDNA.  
(B) Variation of G7731A mtDNA proportions among oocytes obtained from 
three F5 female mice. G7731A mtDNA proportions were estimated by using 
oocytes obtained by ovarian hyperstimulation of F5 female 
mito-mice-tRNALys7731 with high proportions of G7731A mtDNA. 
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Fig. 6 
Characterization of F5 male mito-mice-tRNA
Lys7731 according to phenotypes 
associated with mitochondrial diseases.  
Comparison of (A) body length and (B) muscle (grip) strength between B6 
mice (n=3) and F5 mito-mice-tRNA
Lys7731 carrying low (13%–15%; n = 3), 
intermediate (37%–56%; n = 3), and high (76%–84%; n = 3) proportions of 
G7731A mtDNA. Body length and grip strength were measured at 4 months 
after birth. Data are presented as means ± SD. *, P < 0.05; **, P < 0.01.  
(C) Comparison of activities of mitochondrial respiratory complexes (I+III, II+III, 
and IV) between B6 mice and F5 mito-mice-tRNA
Lys7731 carrying high 
proportions (76–84%) of G7731A mtDNA in the skeletal muscle and the kidney 
at 4 months after birth. Respiratory complex I, complex II, complex III, and 
complex IV are components of the electron-transport chain. Enhanced activity 
of complex II+III in mito-mice-tRNALys7731 would be due to compensatory 
activation of complex II, which is controlled exclusively by nuclear DNA. Data 
are presented as means ± SD (n = 3). *, P < 0.05; **, P < 0.01. 
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Fig. 7 
Analyses of metabolic parameters related to mitochondrial diseases by 
using peripheral blood from mito-mice-tRNALys7731 with high proportions of 
G7731A mtDNA.  
(A) Blood urea nitrogen.  
(B) Hematocrit.  
(C) Blood glucose levels before and after glucose administration.  
(D) Blood lactate levels before and after glucose administration.  
No statistically significant differences between B6 and mito-mice-tRNALys7731 with 
high proportions of G7731A mtDNA were obtained. Data are presented as mean 
± SD (n = 3).  
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Fig. 8 
Histopathologic analysis to identify ragged red fibers (RRF) in skeletal 
muscle.  
Cryosections (thickness, 10 µm) of skeletal muscle were stained by using 
modified Gomori trichrome for histopathologic analysis to identify RRF. No RRF 
were present in mito-mice-tRNALys7731 with high proportions of G7731A mtDNA. 
Bar, 50 μm. 
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Fig. 9 
Morphology and histopathologic analysis of kidney.  
(A) Morphology of kidneys from B6 mouse (left) and mito-mouse-tRNA
Lys7731 
with 76% G7731A mtDNA (right). Bar, 1 cm.  
(B) Histopathology of the renal cortex of kidneys from B6 mice (left) and 
mito-mouse-tRNALys7731 with 76% G7731A mtDNA (right). Formalin-fixed, 
paraffin-embedded sections (thickness, 5 μm) were stained with hematoxylin 
and eosin.  
No renal failure was noted in mito-mice-tRNALys7731. Bar, 50 μm. 
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Fig. 10  
Mitochondrial disease–related parameters that can be examined without 
euthanizing aged mito-mice-tRNALys7731.  
Study populations comprised aged B6 mice (n = 6) and aged 
mito-mice-tRNALys7731 with low (less than 5% in tail tissue; n = 4) and high (n = 4; 
70%, 70%, 72%, and 75% in tail tissue) levels of G7731A mtDNA in tails at 4 
weeks after birth. Disease-related parameters were compared at 26 months after 
birth.  
Intergroup comparison of (A) body length, (B) grip strength, (C) hematocrit, (D) 
blood lactate level, (E) BUN value, and (F) blood glucose level.  
Data are presented as means ±SD. *, P < 0.05; **, P < 0.01. 
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Fig. 11  
Kaplan–Meier survival curves of B6 mice (n = 6) and mito-mice-tRNALys7731 
with low (less than 5%; n = 4) and high (70% to 75%; n = 4) levels of G7731A 
mtDNA.  
Median survival times were 26 months for B6 mice, 28 months for 
mito-mice-tRNALys7731 with low levels, and 27 months for mito-mice-tRNALys7731 
with high levels.  
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Fig. 12 
Skeletal muscle abnormalities in aged mito-mice-tRNALys7731.  
(A) Macroscopic evidence of muscle atrophy in the quadriceps of 
mito-mice-tRNALys7731 with high levels of G7731A mtDNA. Scale bar, 5 mm.  
(B) Histopathologic analysis of skeletal muscles to identify RRFs. Cryosections 
(thickness, 10 µm) of soleus muscle fibers were stained by using modified 
Gomori trichrome to identify RRFs. No RRFs were present even in aged 
mito-mice-tRNALys7731 with high levels of G7731A mtDNA. Scale bar, 50 μm.  
Genotyping of skeletal muscle (soleus) showed that the sample from the low 
group contained 5% G7731A mtDNA, whereas the sample from the high group 
contained 65% G7731A mtDNA. 
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Fig. 13 
Renal abnormalities in aged mito-mice-tRNALys7731.  
(A) Macroscopic evidence of anemic kidneys in mito-mice-tRNALys7731 with 
high levels of G7731A mtDNA.  
(B) Hemotoxylin and eosin (H&E) staining of formalin-fixed, paraffin-embedded 
sections (thickness, 5 μm) of renal cortex revealed dilated lumens of renal 
tubules and casts (arrowheads) in mito-mice-tRNALys7731 with high levels of 
G7731A mtDNA. Scale bar, 50 μm.  
(C) Histochemical analysis of mitochondrial respiratory enzyme activities in the 
kidney. Tissue sections were stained for COX (brown) and SDH (blue). Cells 
that had lost COX activity were blue because of the absence of COX activity. 
Scale bar, 50 μm.  
Genotyping of kidney tissue showed that the sample from the low group 
contained 10% G7731A mtDNA, whereas the sample from the high group 
contained 62% G7731A mtDNA. 
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